JP3828891B2 - 親油性薬物の水溶性誘導体 - Google Patents

親油性薬物の水溶性誘導体 Download PDF

Info

Publication number
JP3828891B2
JP3828891B2 JP2003562632A JP2003562632A JP3828891B2 JP 3828891 B2 JP3828891 B2 JP 3828891B2 JP 2003562632 A JP2003562632 A JP 2003562632A JP 2003562632 A JP2003562632 A JP 2003562632A JP 3828891 B2 JP3828891 B2 JP 3828891B2
Authority
JP
Japan
Prior art keywords
water
drug
reference standard
group
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003562632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515476A5 (enExample
JP2005515476A (ja
Inventor
リ，ミン
ウー，ロバート，エス．
ツァイ，ジェーン，エス．，シー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005515476A publication Critical patent/JP2005515476A/ja
Publication of JP2005515476A5 publication Critical patent/JP2005515476A5/ja
Application granted granted Critical
Publication of JP3828891B2 publication Critical patent/JP3828891B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9473—Anticonvulsants, e.g. phenobarbitol, phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
JP2003562632A 2002-01-25 2003-01-23 親油性薬物の水溶性誘導体 Expired - Fee Related JP3828891B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/057,762 US7029918B2 (en) 2002-01-25 2002-01-25 Water-soluble derivatives of lipophilic drugs
PCT/EP2003/000655 WO2003062819A2 (en) 2002-01-25 2003-01-23 Water- soluble derivatives of lipophilic drugs

Publications (3)

Publication Number Publication Date
JP2005515476A JP2005515476A (ja) 2005-05-26
JP2005515476A5 JP2005515476A5 (enExample) 2005-12-22
JP3828891B2 true JP3828891B2 (ja) 2006-10-04

Family

ID=27609480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003562632A Expired - Fee Related JP3828891B2 (ja) 2002-01-25 2003-01-23 親油性薬物の水溶性誘導体

Country Status (6)

Country Link
US (2) US7029918B2 (enExample)
EP (1) EP1468295A2 (enExample)
JP (1) JP3828891B2 (enExample)
AU (1) AU2003215543A1 (enExample)
CA (1) CA2473498A1 (enExample)
WO (1) WO2003062819A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059547A2 (en) * 2003-12-12 2005-06-30 Inverness Medical Switzerland Gmbh Assay
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH568996A5 (enExample) 1968-05-07 1975-11-14 Hoffmann La Roche
US3819602A (en) * 1968-05-07 1974-06-25 Hoffmann La Roche 7-chloro-5-(2-fluorophenyl)-1-(2-hydroxyethyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one and esters thereof
US3567710A (en) 1968-06-03 1971-03-02 Hoffmann La Roche Process for the preparation of 1,3-dihydro-2h-1,4-benzodiazepin-2-ones
US4046636A (en) 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
US4043989A (en) 1975-09-11 1977-08-23 Syva Company Oxazepam derivatives for immunoassay reagents
US4083948A (en) 1977-04-04 1978-04-11 Hoffmann-La Roche, Inc. Benzodiazepine radioimmunoassay using I125-label
US4243654A (en) 1978-09-11 1981-01-06 Syva Company Oxazepam derivatives for immunoassay reagents
US4717582A (en) 1986-05-22 1988-01-05 The Dow Chemical Company Method and apparatus for controlling the density of a foam
ATE132974T1 (de) * 1986-10-24 1996-01-15 Abbott Lab Test, indikatoren, immunogene und antikörper für benzodiazepine
US5219747A (en) * 1987-01-27 1993-06-15 Hoffmann-La Roche Inc. Immunoassay for tetrahydrocannabinol metabolites
US5144030A (en) 1987-02-17 1992-09-01 Abbott Laboratories Fluorescene polarization immunoassay for tetrahydrocannabinoids
US4777169A (en) 1987-07-24 1988-10-11 Hoffmann-La Roche Inc. Benzodiazepine derivatives
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5237057A (en) 1992-04-06 1993-08-17 Biosite Diagnostics, Inc. Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
CA2167362A1 (en) 1995-02-10 1996-08-11 Alexei Dmitri Klimov Apparatus and method for conducting a binding assay on an absorbent carrier material
EP1066523A2 (en) 1998-03-27 2001-01-10 Microgenics Corporation Confirmatory assays for small molecule drugs
US5847128A (en) 1998-05-29 1998-12-08 Virginia Commonwealth University Water soluble derivatives of cannabinoids
KR20030008153A (ko) 2000-06-22 2003-01-24 파모스 코포레이션 신규 비-향정신성 카나비노이드

Also Published As

Publication number Publication date
CA2473498A1 (en) 2003-07-31
US20060024832A1 (en) 2006-02-02
EP1468295A2 (en) 2004-10-20
AU2003215543A1 (en) 2003-09-02
WO2003062819A3 (en) 2004-04-01
WO2003062819A2 (en) 2003-07-31
US20030153096A1 (en) 2003-08-14
JP2005515476A (ja) 2005-05-26
US7029918B2 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
JP5031585B2 (ja) ５−フルオロ−ウラシル免疫測定法
US5464767A (en) Reagents and methods for the quantification of total doxepins in biological fluids
JPH0819117B2 (ja) テトラヒドロカンナビノール誘導体
EP2950104B1 (en) Immunoassay for compounds of the nbome family
CA1102789A (en) Immunological determination
US4107285A (en) Radioimmunoassay for methaqualone
US5741715A (en) Quinidine immunoassay and reagents
JP3828891B2 (ja) 親油性薬物の水溶性誘導体
US3976763A (en) Chlorpromazine assay
JP2732825B2 (ja) 新規なベンゾジアゼピン−タンパク質結合体
JP2008519793A (ja) イムノアッセイに有用なインジナビル誘導体
JP2682716B2 (ja) ｇｅｍ―ジフェニル誘導体および免疫学的検定法への使用
EP0641439B1 (en) Reagents and methods for the quantification of imipramine or desipramine in biological fluids
JP2001513876A (ja) マイコフェノリック酸アッセイのための試薬
JPH0727763A (ja) １α，２５（ＯＨ）２ビタミンＤ３に対する抗体及びその用途
US10775394B2 (en) Immunoassay for phenethylamines of the 2C and DO sub-families
JP3022942B2 (ja) 新規標識カルバマゼピン類似体
WO1999042840A1 (en) Immunoassays for determination of lsd and lsd metabolites
US4182879A (en) N-[3-methyl-4-(2-methyl-4-oxo-3,4-dihydro-quinazolin-3-yl)phenyl]succinamic acid
US4387086A (en) Organic compounds
JPH0317300B2 (enExample)
JPS6224146A (ja) プロスタグランジンｉ↓２誘導体の酵素免疫測定法
JPS6072863A (ja) 新規なジソピラミド査導体ならびにその高分子物質結合体
JPH0920773A (ja) イソキノリンスルホンアミド誘導体及びその測定方法

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20051111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060707

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees